Frazier Life Sciences Management L.P. bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,184,840 shares of the company’s stock, valued at approximately $15,758,000. Frazier Life Sciences Management L.P. owned 1.93% of Dyne Therapeutics at […]
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) COO Susanna Gatti High sold 80,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $30.24, for a total value of $2,419,200.00. Following the completion of the transaction, the chief operating officer now owns 154,062 […]
Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) have earned an average rating of “Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price […]
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s stock price was down 3% during mid-day trading on Thursday . The stock traded as low as $27.57 and last traded at $27.89. Approximately 552,733 shares were traded during trading, a decline of 75% from the average daily volume of 2,206,098 shares. The stock had previously closed […]
Dyne Therapeutics, Inc. (NYSE:DYN – Get Free Report) shares rose 5.9% during mid-day trading on Tuesday . The company traded as high as $19.57 and last traded at $19.09. Approximately 990,808 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 8,243,103 shares. The stock had previously closed at […]